Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.8 ILa | -1.01% | -2.97% | +180.00% |
04-30 | XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-29 | Top Premarket Gainers | MT |
Business Summary
Number of employees: 5
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 16-03-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 57 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 | |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Director/Board Member | 46 | 14-12-07 | |
Director/Board Member | 57 | 15-02-28 | |
Director/Board Member | 63 | 14-12-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 514,205,799 | 479,737,353 ( 93.30 %) | 0 | 93.30 % |
Company contact information
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.comSector
1st Jan change | Capi. | |
---|---|---|
+180.00% | 14.71M | |
+44.48% | 55.07B | |
+44.25% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- XTLB Stock
- Company XTL Biopharmaceuticals Ltd.